Cleveland Clinic and IBM’s Blueprint for Discovering Novel Immunotherapy Targets Using Artificial Intelligence
Predicting the immunogenicity of peptide antigens attached to major histocompatibility complex (MHC) molecules is critical for developing new immunotherapies and better understanding human immune responses. While existing techniques rely on simple sequence representations, they neglect the complex chemical mechanisms that drive peptide recognition. Researchers from Cleveland Clinic and IBM collaborated to create supervised and unsupervised…
